1768 related articles for article (PubMed ID: 18448208)
1. Generation and evaluation of the trivalent inactivated reassortant vaccine using human, avian, and swine influenza A viruses.
Du N; Li W; Li Y; Liu S; Sui Y; Qu Z; Wang Y; Du Y; Xu B
Vaccine; 2008 Jun; 26(23):2912-8. PubMed ID: 18448208
[TBL] [Abstract][Full Text] [Related]
2. Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses.
Shi H; Liu XF; Zhang X; Chen S; Sun L; Lu J
Vaccine; 2007 Oct; 25(42):7379-84. PubMed ID: 17870216
[TBL] [Abstract][Full Text] [Related]
3. Generation and evaluation of an H9N1 influenza vaccine derived by reverse genetics that allows utilization of a DIVA strategy for control of H9N2 avian influenza.
Wu R; Chen Q; Zheng L; Chen J; Sui Z; Guan Y; Chen Z
Arch Virol; 2009; 154(8):1203-10. PubMed ID: 19543688
[TBL] [Abstract][Full Text] [Related]
4. Development of Eurasian H7N7/PR8 high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine.
Jadhao SJ; Achenbach J; Swayne DE; Donis R; Cox N; Matsuoka Y
Vaccine; 2008 Mar; 26(14):1742-50. PubMed ID: 18336962
[TBL] [Abstract][Full Text] [Related]
5. Generation and evaluation of reassortant influenza vaccines made by reverse genetics for H9N2 avian influenza in Korea.
Song JM; Lee YJ; Jeong OM; Kang HM; Kim HR; Kwon JH; Kim JH; Seong BL; Kim YJ
Vet Microbiol; 2008 Aug; 130(3-4):268-76. PubMed ID: 18374520
[TBL] [Abstract][Full Text] [Related]
6. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.
Desheva JA; Lu XH; Rekstin AR; Rudenko LG; Swayne DE; Cox NJ; Katz JM; Klimov AI
Vaccine; 2006 Nov; 24(47-48):6859-66. PubMed ID: 17050041
[TBL] [Abstract][Full Text] [Related]
7. Genetic and antigenic relatedness of H3 subtype influenza A viruses isolated from avian and mammalian species.
Yassine HM; Lee CW; Suarez DL; Saif YM
Vaccine; 2008 Feb; 26(7):966-77. PubMed ID: 18206275
[TBL] [Abstract][Full Text] [Related]
8. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant.
Sui Z; Chen Q; Wu R; Zhang H; Zheng M; Wang H; Chen Z
Arch Virol; 2010 Apr; 155(4):535-44. PubMed ID: 20195654
[TBL] [Abstract][Full Text] [Related]
9. Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses.
Altstein AD; Gitelman AK; Smirnov YA; Piskareva LM; Zakharova LG; Pashvykina GV; Shmarov MM; Zhirnov OP; Varich NP; Ilyinskii PO; Shneider AM
Arch Virol; 2006 May; 151(5):921-31. PubMed ID: 16292596
[TBL] [Abstract][Full Text] [Related]
10. Generation and evaluation of a high-growth reassortant H9N2 influenza A virus as a pandemic vaccine candidate.
Chen H; Subbarao K; Swayne D; Chen Q; Lu X; Katz J; Cox N; Matsuoka Y
Vaccine; 2003 May; 21(17-18):1974-9. PubMed ID: 12706686
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza.
Pushko P; Tumpey TM; Van Hoeven N; Belser JA; Robinson R; Nathan M; Smith G; Wright DC; Bright RA
Vaccine; 2007 May; 25(21):4283-90. PubMed ID: 17403562
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a high-growth reassortant H1N1 influenza virus vaccine against the classical swine H1N1 subtype influenza virus in mice and pigs.
Wen F; Yu H; Yang FR; Huang M; Yang S; Zhou YJ; Li ZJ; Tong GZ
Arch Virol; 2014 Nov; 159(11):2957-67. PubMed ID: 24957653
[TBL] [Abstract][Full Text] [Related]
13. A cell culture-derived whole-virus H9N2 vaccine induces high titer antibodies against hemagglutinin and neuraminidase and protects mice from severe lung pathology and weight loss after challenge with a highly virulent H9N2 isolate.
Wodal W; Falkner FG; Kerschbaum A; Gaiswinkler C; Fritz R; Kiermayr S; Portsmouth D; Savidis-Dacho H; Coulibaly S; Piskernik C; Hohenadl C; Howard MK; Kistner O; Barrett PN; Kreil TR
Vaccine; 2012 Jun; 30(31):4625-31. PubMed ID: 22580355
[TBL] [Abstract][Full Text] [Related]
14. Generation of reassortant influenza vaccines by reverse genetics that allows utilization of a DIVA (Differentiating Infected from Vaccinated Animals) strategy for the control of avian influenza.
Lee CW; Senne DA; Suarez DL
Vaccine; 2004 Aug; 22(23-24):3175-81. PubMed ID: 15297071
[TBL] [Abstract][Full Text] [Related]
15. A live bivalent influenza vaccine based on a H9N2 virus strain.
Wu R; Guan Y; Yang Z; Chen J; Wang H; Chen Q; Sui Z; Fang F; Chen Z
Vaccine; 2010 Jan; 28(3):673-80. PubMed ID: 19892041
[TBL] [Abstract][Full Text] [Related]
16. Protective efficacy of a high-growth reassortant H1N1 influenza virus vaccine against the European Avian-like H1N1 swine influenza virus in mice and pigs.
Ruan BY; Wen F; Gong XQ; Liu XM; Wang Q; Yu LX; Wang SY; Zhang P; Yang HM; Shan TL; Zheng H; Zhou YJ; Tong W; Gao F; Tong GZ; Yu H
Vet Microbiol; 2018 Aug; 222():75-84. PubMed ID: 30080677
[TBL] [Abstract][Full Text] [Related]
17. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function.
Sambhara S; Kurichh A; Miranda R; Tumpey T; Rowe T; Renshaw M; Arpino R; Tamane A; Kandil A; James O; Underdown B; Klein M; Katz J; Burt D
Cell Immunol; 2001 Aug; 211(2):143-53. PubMed ID: 11591118
[TBL] [Abstract][Full Text] [Related]
18. Potency of an inactivated avian influenza vaccine prepared from a non-pathogenic H5N1 reassortant virus generated between isolates from migratory ducks in Asia.
Isoda N; Sakoda Y; Kishida N; Soda K; Sakabe S; Sakamoto R; Imamura T; Sakaguchi M; Sasaki T; Kokumai N; Ohgitani T; Saijo K; Sawata A; Hagiwara J; Lin Z; Kida H
Arch Virol; 2008; 153(9):1685-92. PubMed ID: 18651092
[TBL] [Abstract][Full Text] [Related]
19. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
[TBL] [Abstract][Full Text] [Related]
20. Development of vaccine strains of H5 and H7 influenza viruses.
Soda K; Sakoda Y; Isoda N; Kajihara M; Haraguchi Y; Shibuya H; Yoshida H; Sasaki T; Sakamoto R; Saijo K; Hagiwara J; Kida H
Jpn J Vet Res; 2008 Jan; 55(2-3):93-8. PubMed ID: 18318111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
